Unassociated Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2010

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION

(Translation of registrant’s name into English)

48th Floor, Bank of China Tower

1 Garden Road

Central

Hong Kong S.A.R.

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x

Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o

No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.

EXPLANATORY NOTE

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this Form 6-K is filed, and the Company does not intend to update any of the forward-looking statements after the date this Report on Form 6-K is filed to confirm these statements to actual results, unless required by law.

The forward-looking statements included in this Form 6-K are subject to risks, uncertainties and assumptions about our businesses and business environments. These statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual results of our operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations; changing legislation or regulatory environments; requirements or changes affecting the businesses in which the Company is engaged; industry trends, including factors affecting supply and demand; labor and personnel relations; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; general economic conditions; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission.

Results of Operations and Financial Condition

Following this cover page are the unaudited consolidated financial results for the three months and nine months ended December 31, 2009 of China Cord Blood Corporation (the “Company”).

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of December 31 and March 31, 2009

	December 31, 2009				March 31, 2009
	US$		RMB		RMB
	(in thousands except redemption value and number of shares)
ASSETS
Current assets
Cash and cash equivalents		56,560		386,069		161,406
Accounts receivable, less allowance for doubtful accounts (December 31, 2009: RMB9,251; March 31, 2009: RMB 6,170)		8,361		57,071		49,763
Inventories		843		5,757		6,501
Prepaid expenses and other receivables		1,511		10,312		7,978
Deferred tax assets		476		3,249		1,846
Total current assets		67,751		462,458		227,494
Property, plant and equipment, net		37,553		256,331		236,740
Non-current prepayments and deposits		1,735		11,846		27,184
Non-current accounts receivable, less allowance for doubtful accounts (December 31, 2009: RMB5,390; March 31, 2009: RMB2,223)		24,007		163,872		91,761
Inventories		4,153		28,348		26,069
Intangible asset, net		3,888		26,540		27,268
Available-for-sale equity securities		8,780		59,932		26,242
Deferred reverse recapitalization costs		-		-		33,633
Deferred tax assets		89		609		-
Total assets		147,956		1,009,936		696,391

LIABILITIES
Current liabilities
Bank loan		6,592		45,000		-
Accounts payable		1,274		8,693		5,128
Accrued expenses and other payables		2,853		19,472		19,269
Deferred revenue		5,135		35,049		18,351
Amounts due to related parties		384		2,621		-
Income tax payable		584		3,989		4,321
Total current liabilities		16,822		114,824		47,069
Deferred revenue		12,530		85,530		74,231
Other non-current liabilities		2,113		14,427		13,551
Deferred tax liabilities		414		2,827		4,017
Total liabilities		31,879		217,608		138,868

Commitments and contingencies
Redeemable ordinary shares of China Cord Blood Services Corporation US$0.0001 par value, 14,614,140 shares issued and outstanding as of March 31, 2009 (redemption value of US$51,088,745 as of March 31, 2009)		-		-		386,577

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of December 31 and March 31, 2009 - (continued)

	December 31, 2009				March 31, 2009
	US$		RMB		RMB
	(in thousands except redemption value and number of shares)
EQUITY
China Cord Blood Corporation shareholders’ equity
Ordinary shares US$0.0001 par value, 250,000,000 shares authorized, 43,237,100 shares and 66,182,726 shares issued and outstanding as of March 31, 2009 and December 31, 2009, respectively		7		45		34
Additional paid-in capital		102,233		697,834		140,745
Accumulated other comprehensive loss		2,055		14,023		(19,319	)
Retained earnings		10,425		71,161		44,082
Total China Cord Blood Corporation shareholders’ equity		114,720		783,063		165,542
Noncontrolling interests		1,357		9,265		5,404
Total equity		116,077		792,328		170,946
Total liabilities, redeemable ordinary shares and equity		147,956		1,009,936		696,391

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months and Nine Months Ended December 31, 2009 and 2008

	Three months ended December 31,									Nine months ended December 31,
	2009						2008			2009						2008
	US$			RMB			RMB			US$			RMB			RMB
	(in thousands except per share)

Revenues		10,095			68,905			55,795			27,941			190,731			137,730
Direct costs		(2,451	)		(16,727	)		(13,561	)		(7,415	)		(50,615	)		(35,736	)
Gross profit		7,644			52,178			42,234			20,526			140,116			101,994
Operating expenses
Sales and marketing		(1,526	)		(10,416	)		(6,636	)		(3,945	)		(26,928	)		(21,683	)
General and administrative		(2,442	)		(16,669	)		(10,718	)		(5,991	)		(40,896	)		(21,696	)
Total operating expenses		(3,968	)		(27,085	)		(17,354	)		(9,936	)		(67,824	)		(43,379	)
Operating income		3,676			25,093			24,880			10,590			72,292			58,615
Other income/(expense), net
Interest income		336			2,292			882			739			5,047			2,793
Interest expense		(102	)		(695	)		-			(265	)		(1,812	)		-
Exchange gain/(loss)		6			39			(107	)		88			602			(188	)
Write-off of deferred offering and reverse recapitalization costs		-			-			215			(3,159	)		(21,566	)		(9,473	)
Impairment loss on available-for-sale equity securities		-			-			(9,828	)		-			-			(37,426	)
Others		(8	)		(51	)		1,809			48			326			663
Total other income/(expense), net		232			1,585			(7,029	)		(2,549	)		(17,403	)		(43,631	)
Income before income tax		3,908			26,678			17,851			8,041			54,889			14,984
Income tax expense		(795	)		(5,431	)		(4,012	)		(2,574	)		(17,572	)		(11,810	)
Net income		3,113			21,247			13,839			5,467			37,317			3,174
Income attributable to redeemable noncontrolling interests		-			-			-			(51	)		(347	)		-
Income attributable to noncontrolling interests		(183	)		(1,246	)		(1,003	)		(575	)		(3,922	)		(2,598	)
Net income attributable to China Cord Blood Corporation shareholders		2,930			20,001			12,836			4,841			33,048			576

Net income/(loss) per share:
Attributable to ordinary shares
-Basic		0.05			0.31			0.11			0.06			0.44			(0.32	)
-Diluted		0.04			0.29			0.11			0.06			0.42			(0.32	)
Attributable to redeemable ordinary shares
-Basic		N/A			N/A			0.54			0.24			1.65			0.98
-Diluted		N/A			N/A			0.54			0.24			1.62			0.98

Other Events

On March 5, 2010, Company issued a press release announcing the unaudited consolidated financial results for the three months and nine months ended December 31, 2009. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.	Description

99.1	Press Release, dated March 5, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHINA CORD BLOOD CORPORATION

	By:	/s/ Albert Chen
	Name:	Albert Chen
	Title:	Chief Financial Officer

Dated: March 5, 2010